肝移植作為一種有效的治療手段廣泛地應(yīng)用于兒童終末期肝病的治療。為了預(yù)防可能發(fā)生的排斥反應(yīng)，患兒需要長(zhǎng)期服用免疫抑制劑。他克莫司是一種具有強(qiáng)效免疫抑制特性的大環(huán)內(nèi)酯類(lèi)藥物，以他克莫司為主的免疫抑制方案可以減少排斥反應(yīng)和激素抵抗型排斥反應(yīng)的發(fā)生率。探討了基因多態(tài)性、減少劑量或撤藥、不同劑型之間轉(zhuǎn)換以及免疫抑制劑短期、長(zhǎng)期生存結(jié)果對(duì)兒童肝移植術(shù)后的影響，以期優(yōu)化他克莫司的給藥方案，為器官移植患兒的他克莫司藥物監(jiān)測(cè)和劑量調(diào)整提供參考。

As an effective treatment,liver transplantation is widely used in the treatment of end-stage liver disease in children.In order to prevent possible rejection,children need to take long-term immunosuppressants.Tacrolimus is a macrolide drug with strong immunosuppressive properties,and the tacrolimus-based immunosuppressant regimen can reduce the incidence of rejection and hormone resistant rejection.This article discusses the effects of gene polymorphism,dose reduction or withdrawal,conversion between different dosage forms,and short-term and long-term survival results of immunosuppressants on children after liver transplantation,hoping to optimize the drug delivery scheme of tacrolimus,and provide reference for drug monitoring and dose adjustment of tacrolimus in children undergoing organ transplantation.